HPV prevalence at enrolment and at 12 months among sexually active subjects
| Enrolment | 12 months | |||||
|---|---|---|---|---|---|---|
| Control n (%) | Vaccine n (%) | Total n (%) | Control n (%) | Vaccine n (%) | Total n (%) | |
| Swab results available/sexually active | 33/47 (70.2) | 84/95 (88.4) | 117/142 (82.4) | 37/45 (82.2) | 85/91 (93.4) | 122/136 (89.7) |
| Any HPV type | ||||||
| Yes | 25 (75.8) | 61 (72.6) | 86 (73.5) | 25 (67.6) | 66 (77.6) | 91 (74.6) |
| Any high risk HPV | ||||||
| Yes | 18 (54.5) | 46 (54.8) | 64 (54.7) | 12 (32.4) | 50 (58.8) | 62 (50.8) |
| HPV 16/18 | ||||||
| Yes | 4 (12.1) | 13 (15.5) | 17 (14.5) | 3 (8.1) | 5 (5.9) | 8 (6.6) |
| Number of HPV genotypes | ||||||
| None | 8 (24.2) | 23 (27.4) | 31 (26.5) | 12 (32.4) | 19 (22.4) | 31 (25.4) |
| 1 | 7 (21.2) | 20 (23.8) | 27 (23.1) | 11 (29.7) | 18 (21.2) | 29 (23.8) |
| 2 | 9 (27.3) | 16 (19.0) | 25 (21.4) | 2 (5.4) | 19 (22.4) | 21 (17.2) |
| 3 | 4 (12.1) | 11 (13.1) | 15 (12.8) | 4 (10.8) | 14 (16.5) | 18 (14.8) |
| 4 or more | 5 (15.2) | 14 (16.7) | 19 (16.2) | 8 (21.6) | 15 (17.6) | 23 (18.9) |
| Swab results available at both visits/sexually active at both visits | 24/39 (61.5) | 73/84 (86.9) | 97/123 (78.9) | |||
| Any new HPV type | ||||||
| Yes | 16 (66.7) | 49 (67.1) | 65 (67.0) | |||
| Any new high risk HPV | ||||||
| Yes | 7 (29.2) | 34 (46.6) | 41 (42.3) | |||
| Any new HPV-16/18 | ||||||
| Yes | 2 (8.3) | 1 (1.4) | 3 (3.1) | |||
| Any persistent HPV | ||||||
| Yes | 10 (41.7) | 22 (30.1) | 32 (33.0) | |||
| Any persistent high risk HPV | ||||||
| Yes | 5 (20.8) | 16 (21.9) | 21 (21.6) | |||
HPV, human papillomavirus.